Literature DB >> 2297658

Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.

P C Pinto1, E Hu, M Bernstein-Singer, L Pinter-Brown, S Govindarajan.   

Abstract

Five patients with lymphoproliferative malignancies and chronic hepatitis B suffered severe acute hepatic injury after the withdrawal of multiagent chemotherapy that included high-dose corticosteroid. Four patients died of hepatic failure, three of whom received corticosteroid as treatment for the hepatic injury. We believe that the cause of this entity is massive immune-associated cytolysis of hepatitis B virus infected hepatocytes occurring after a period of immunosuppression and increased viral replication. The literature regarding this complication of chemotherapy and its pathophysiology is reviewed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297658     DOI: 10.1002/1097-0142(19900215)65:4<878::aid-cncr2820650409>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  Extrahepatic manifestations of chronic viral hepatitis.

Authors:  N T Pyrsopoulos; K R Reddy
Journal:  Curr Gastroenterol Rep       Date:  2001-02

2.  Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists.

Authors:  Fiona L Day; Emma Link; Karin Thursky; Danny Rischin
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

3.  Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.

Authors:  T Sato; J Kato; J Kawanishi; K Kogawa; M Ohya; S Sakamaki; Y Niitsu
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

4.  Management of hepatitis B reactivation in patients receiving cancer chemotherapy.

Authors:  Yi-Wen Huang; Raymond T Chung
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

5.  Recovery from life-threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamivudine therapy.

Authors:  F ter Borg; S Smorenburg; R A de Man; R C Rietbroek; R A Chamuleau; E A Jones
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

6.  Association between hepatitis B virus and pancreatic cancer.

Authors:  Manal M Hassan; Donghui Li; Adel S El-Deeb; Robert A Wolff; Melissa L Bondy; Marta Davila; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

7.  Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.

Authors:  Takeaki Takenaka; Kuniaki Itoh; Takayo Suzuki; Atae Utsunomiya; Shin Matsuda; Takaaki Chou; Toshiaki Sai; Masayuki Sano; Susumu Konda; Tatsuji Ohno; Chikara Mikuni; Kijoh Deura; Takashi Yamada; Fumi Mizorogi; Haruhisa Nagoshi; Masao Tomonaga; Tomomitsu Hotta; Kohichi Kawano; Keitaro Tsushita; Masami Hirano; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

8.  Rituximab administration and reactivation of HBV.

Authors:  Yutaka Tsutsumi; Reiki Ogasawara; Yusuke Kamihara; Shinichi Ito; Yoshiya Yamamoto; Junji Tanaka; Masahiro Asaka; Masahiro Imamura
Journal:  Hepat Res Treat       Date:  2010-12-01

9.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.